{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T07:35:14Z","timestamp":1791876914018,"version":"4.3.4"},"reference-count":29,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2020,2,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The anti-CD19 chimeric antigen receptor (CAR)\u2013T cell therapy tisagenlecleucel was evaluated in the global, phase 2 JULIET study in adult patients with relapsed\/refractory diffuse large B-cell lymphoma (DLBCL). We correlated tisagenlecleucel cellular kinetics with clinical\/product parameters in 111 patients treated in JULIET. Tisagenlecleucel persistence in responders and nonresponders, respectively, was demonstrated for 554 and 400 days maximum by flow cytometry and for 693 and 374 days maximum by quantitative polymerase chain reaction (qPCR). No relationships were identified between cellular kinetics (qPCR) and product characteristics, intrinsic\/extrinsic factors, dose, or immunogenicity. Most patients with 3-month response had detectable transgene at time of response and continued persistence for \u22656 months. Expansion (maximal expansion of transgene\/CAR-positive T-cell levels in vivo postinfusion [Cmax]) was potentially associated with response duration but this did not reach statistical significance (hazard ratio for a twofold increase in Cmax, 0.79; 95% confidence interval, 0.61-1.01). Tisagenlecleucel expansion was associated with cytokine-release syndrome (CRS) severity and tocilizumab use; no relationships were observed with neurologic events. Transgene levels were associated with B-cell levels. Dose was associated with CRS severity, but this was not statistically significant after adjusting for baseline tumor burden. In contrast to the results from B-cell precursor acute lymphoblastic leukemia (B-ALL) and chronic lymphocytic leukemia, similar exposure was observed in DLBCL in this study regardless of response and expansion was lower in DLBCL than B-ALL, likely from differences in cancer location and\/or T-cell intrinsic factors. Relationships between expansion and CRS severity, and lack of relationships between dose and exposure, were similar between DLBCL and B-ALL. Tisagenlecleucel cellular kinetics in adult relapsed\/refractory DLBCL improve current understanding of in vivo expansion and its relationships with safety\/efficacy endpoints. This trial was registered at www.clinicaltrials.gov as #NCT02445248.<\/jats:p>","DOI":"10.1182\/bloodadvances.2019000525","type":"journal-article","created":{"date-parts":[[2020,2,11]],"date-time":"2020-02-11T17:06:24Z","timestamp":1581440784000},"page":"560-572","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":144,"title":["Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed\/refractory DLBCL"],"prefix":"10.1182","volume":"4","author":[{"given":"Rakesh","family":"Awasthi","sequence":"first","affiliation":[{"name":"Novartis Institutes for BioMedical Research, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7803-2366","authenticated-orcid":false,"given":"Lida","family":"Pacaud","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Waldron","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"Hematology Department, Peter MacCallum Cancer Center, University of Melbourne, Melbourne, Australia;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[{"name":"Division of Hematology and Hemostaseology, Department of Medicine I, Medical University of Vienna, Vienna, Austria;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Borchmann","sequence":"additional","affiliation":[{"name":"Department of Hematology and Oncology, University Hospital of Cologne, Cologne, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4335-2554","authenticated-orcid":false,"given":"Samantha","family":"Jaglowski","sequence":"additional","affiliation":[{"name":"The James Cancer Hospital and Solove Research Institute, The Ohio State University Comprehensive Cancer Center, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Ronan","family":"Foley","sequence":"additional","affiliation":[{"name":"Juravinski Hospital and Cancer Center, McMaster University, Hamilton, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8164-6211","authenticated-orcid":false,"given":"Koen","family":"van Besien","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology, Weill Cornell Medicine and New York-Presbyterian Hospital, New York, NY;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina D.","family":"Wagner-Johnston","sequence":"additional","affiliation":[{"name":"The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie Jos\u00e9","family":"Kersten","sequence":"additional","affiliation":[{"name":"Department of Hematology, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Lymphoma Program, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9541-8666","authenticated-orcid":false,"given":"Gilles","family":"Salles","sequence":"additional","affiliation":[{"name":"Department of Hematology, CHU Lyon-Sud Hospital, Hospices Civils de Lyon, Lyon, France;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard T.","family":"Maziarz","sequence":"additional","affiliation":[{"name":"Center for Hematologic Malignancies, Oregon Health & Science University Knight Cancer Institute, Portland, OR; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00d6zlem","family":"Anak","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"del Corral","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jufen","family":"Chu","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Gershgorin","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iulian","family":"Pruteanu-Malinici","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhijit","family":"Chakraborty","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen Thudium","family":"Mueller","sequence":"additional","affiliation":[{"name":"Novartis Institutes for BioMedical Research, East Hanover, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0816-6729","authenticated-orcid":false,"given":"Edmund K.","family":"Waller","sequence":"additional","affiliation":[{"name":"Bone Marrow and Stem Cell Transplant Center, Winship Cancer Institute of Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2020,2,11]]},"reference":[{"key":"2020021112061391000_B1"},{"issue":"1","key":"2020021112061391000_B2","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1097\/HS9.0000000000000018","article-title":"Chimeric antigen receptor-T cell therapy: practical considerations for implementation in Europe","volume":"2","author":"Buechner","year":"2018","journal-title":"Hemasphere"},{"issue":"5","key":"2020021112061391000_B3","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"key":"2020021112061391000_B4","author":"Kymriah (tisagenlecleucel)","year":"2018"},{"issue":"1","key":"2020021112061391000_B5","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"2020021112061391000_B6","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N Engl J Med"},{"issue":"21","key":"2020021112061391000_B7","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/blood-2017-06-786129","article-title":"Cellular kinetics of CTL019 in relapsed\/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia","volume":"130","author":"Mueller","year":"2017","journal-title":"Blood"},{"issue":"21","key":"2020021112061391000_B8","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"issue":"24","key":"2020021112061391000_B9","doi-asserted-by":"crossref","first-page":"6175","DOI":"10.1158\/1078-0432.CCR-18-0758","article-title":"Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia","volume":"24","author":"Mueller","year":"2018","journal-title":"Clin Cancer Res"},{"key":"2020021112061391000_B10","doi-asserted-by":"crossref","first-page":"3885","DOI":"10.2147\/DDDT.S138765","article-title":"CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia","volume":"12","author":"Vairy","year":"2018","journal-title":"Drug Des Devel Ther"},{"issue":"7","key":"2020021112061391000_B11","doi-asserted-by":"crossref","first-page":"a019091","DOI":"10.1101\/cshperspect.a019091","article-title":"Nuclear DNA content varies with cell size across human cell types","volume":"7","author":"Gillooly","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"issue":"suppl 1","key":"2020021112061391000_B12","first-page":"609","article-title":"Multicenter variability of total metabolic tumor volume estimates in FDG PET","volume":"58","author":"Buvat","year":"2017","journal-title":"J Nucl Med"},{"issue":"16","key":"2020021112061391000_B13","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N Engl J Med"},{"key":"2020021112061391000_B14","author":"RITUXAN (rituximab)"},{"issue":"3","key":"2020021112061391000_B15","first-page":"148","article-title":"Impact of rituximab (rituxan) on the treatment of B-cell non-Hodgkin\u2019s lymphoma","volume":"35","author":"Dotan","year":"2010","journal-title":"P&T"},{"key":"2020021112061391000_B16","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/hon.117_2630","article-title":"Cytokine release syndrome and neurotoxicity by baseline tumor burden in adults with relapsed or refractory diffuse large B-cell lymphoma treated with tisagenlecleucel","volume":"37","author":"Maziarz","year":"2019","journal-title":"Hematol Oncol"},{"key":"2020021112061391000_B17","doi-asserted-by":"crossref","first-page":"112692","DOI":"10.1016\/j.jim.2019.112692","article-title":"A cell-based immunogenicity assay to detect antibodies against chimeric antigen receptor expressed by tisagenlecleucel","volume":"476","author":"Potthoff","year":"2020","journal-title":"J Immunol Methods"},{"key":"2020021112061391000_B18","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2018.36.15_suppl.3044","article-title":"Immunogenicity of tisagenlecleucel in relapsed\/ refractory (R\/R) B-cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) patients [abstract]","volume-title":"J Clin Oncol","author":"Mueller","year":"2018"},{"key":"2020021112061391000_B19","doi-asserted-by":"crossref","unstructured":"Awasthi R , MuellerKT, YanikGA, et al Evaluation of in vivo CAR transgene levels in relapsed\/refractory pediatric and young adult ALL and adult DLBCL tisagenlecleucel-treated patients [abstract]. Blood. 2018;132(suppl 1). Abstract 899.","DOI":"10.1182\/blood-2018-99-116385"},{"issue":"26","key":"2020021112061391000_B20","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"303","key":"2020021112061391000_B21","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"suppl","key":"2020021112061391000_B22","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/hon.2437_6","article-title":"Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R\/R) diffuse large B-cell lymphoma (DLBCL)-an interim analysis","volume":"35","author":"Schuster","year":"2017","journal-title":"Hematol Oncol"},{"issue":"6","key":"2020021112061391000_B23","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1111\/cas.13239","article-title":"Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma","volume":"108","author":"Makita","year":"2017","journal-title":"Cancer Sci"},{"key":"2020021112061391000_B24","unstructured":"Stein A , GruppS, LevineJE, et al CTL019 model-based cellular kinetic analysis of chimeric antigen receptor (CAR) T cells to characterize the impact of tocilizumab on expansion and to identify correlates of cytokine release syndrome severity [abstract]. Blood. 2017;130 (suppl 1). Abstract 2561."},{"issue":"3","key":"2020021112061391000_B25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1208\/s12248-013-9497-z","article-title":"Evaluation of pre-existing antibody presence as a risk factor for posttreatment anti-drug antibody induction: analysis of human clinical study data for multiple biotherapeutics","volume":"15","author":"Xue","year":"2013","journal-title":"AAPS J"},{"key":"2020021112061391000_B26","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hon.2437_7","article-title":"Axicabtagene ciloleucel (axi-cel; KTE-C19) in patients with refractory aggressive non-Hodgkin lymphomas (NHL): primary results of the pivotal trial ZUMA-1 [abstract]","volume":"35","author":"Neelapu","year":"2017","journal-title":"Hematol Oncol"},{"issue":"15","key":"2020021112061391000_B27","doi-asserted-by":"crossref","first-page":"7513","DOI":"10.1200\/JCO.2017.35.15_suppl.7513","article-title":"CR rates in relapsed\/refractory (R\/R) aggressive B-NHL treated with the CD19-directed CAR T-cell product JCAR017 (TRANSCEND NHL 001) [abstract]","volume":"35","author":"Abramson","year":"2017","journal-title":"J Clin Oncol"},{"issue":"6","key":"2020021112061391000_B28","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI85309","article-title":"CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients","volume":"126","author":"Turtle","year":"2016","journal-title":"J Clin Invest"},{"issue":"15 suppl","key":"2020021112061391000_B29","doi-asserted-by":"crossref","first-page":"7562","DOI":"10.1200\/JCO.2019.37.15_suppl.7562","article-title":"Association of high baseline metabolic tumor volume with response following axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"37","author":"Dean","year":"2019","journal-title":"J Clin Oncol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/560\/1634292\/advancesadv2019000525.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/bloodadvances\/article-pdf\/4\/3\/560\/1634292\/advancesadv2019000525.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T01:16:17Z","timestamp":1614388577000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/4\/3\/560\/441053\/Tisagenlecleucel-cellular-kinetics-dose-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,11]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2020,2,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2019000525","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,11]]}}}